Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
08 Dezembro 2023 - 8:07AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment (37)*
AVALON
HOLDINGS CORPORATION
(Name of Issuer)
Class A Common Stock, $0.01 par value
(Title of Class of Securities)
0534P109
(CUSIP Number)
Anil Choudary Nalluri, M.D.
5500 Market Street, Suite 128
Youngstown, Ohio 44512
330-783-1147
(Name,
Address and Telephone Number of Person Authorized to Receive Notices and Communications)
December 7, 2023
(Date of Event which Requires Filing of this Statement)
If the filing person has
previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following
box. ☐
Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See
§240.13d-7 for other parties to whom copies are to be sent.
* |
The remainder of this cover page shall be filled out for a reporting persons initial filing on this form
with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. |
The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities
Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
Persons who respond to the
collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
|
|
|
|
|
|
1. |
|
Names
of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only).
Anil Choudary Nalluri |
2. |
|
Check the Appropriate Box if a
Member of a Group (See Instructions)
(a) ☐ (b) ☐
|
3. |
|
SEC Use Only
|
4. |
|
Source of Funds (See
Instructions) PF |
5. |
|
Check if Disclosure of Legal
Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐ |
6. |
|
Citizenship or Place of
Organization United States |
Number of
Shares
Beneficially
Owned by
Each Reporting
Person With
|
|
7. |
|
Sole Voting Power
969,542 |
|
8. |
|
Shared Voting Power
0 |
|
9. |
|
Sole Dispositive Power
969,542 |
|
10. |
|
Shared Dispositive Power
0 |
11. |
|
Aggregate Amount Beneficially Owned by Each Reporting Person
969,542 |
12. |
|
Check if the Aggregate Amount in
Row (11) Excludes Certain Shares (See Instructions) ☐ |
13. |
|
Percent of Class Represented by
Amount in Row (11) |
14. |
|
Type of Reporting Person (See
Instructions) IN |
2
Item 1. |
Security and Issuer |
This Statement on Schedule 13D (Schedule 13D) relates to the Class A Common Stock, $0.01 par value (the Common
Stock) of Avalon Holdings Corporation, an Ohio corporation (the Issuer), whose principal executive offices are located at One American Way, Warren, Ohio 44484.
Item 2. |
Identity and Background |
This statement is filed by Anil Choudary Nalluri (Dr. Nalluri or the Reporting Person) on behalf of himself and
his wife, Parvati Nalluri and various accounts controlled by them. Dr Nalluris principal business address is 5500 Market Street, Suite 128, Youngstown, Ohio 44512. Dr. Nalluris principal occupation is practicing in the field of
psychiatry. During the past five years, Dr. Nalluri has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) and has not been a party to civil proceedings of a judical or administrative body of
competent jurisdiction, as a result of which Dr. Nalluri was or is subject to a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any
violation with respect to such laws. Dr. Nalluri is a United States citizen.
3
Item 3. |
Source and Amount of Funds or Other Consideration |
Dr. Nalluris purchases of shares of Common Stock have all been made with his personal funds.
Item 4. |
Purpose of Transaction |
The purpose of this filing is to state that Dr. Nalluri is the beneficial owner of greater than 20% of the Common Stock of the issuer.
Doctor Nalluri does not currently have any specific plans or proposals that relate to or would result in any of the actions or
events specified in clauses (a) through (j) of Item 4 of Schedule 13D. Mr. Nalluri reserves the right to change plans and take any and all actions that Dr. Nalluri may deem appropriate to maximize the value of his investments,
including, among other things, purchasing or otherwise acquiring additional securities of the Issuer, selling or otherwise disposing of any securities of the Issuer beneficially owned by him, in each case in the open market or in privately
negotiated transactions, or fomulating other plans or proposals regarding the Issuer or its securities to the extent deemed advisable by Mr. Nalluri is light of his general investment policies, market conditions, subsequent developments
affecting the Issuer and the general business and future prospects of the Issuer.
Item 5. |
Interest in Securities of the Issuer |
(a) Dr. Nalluri beneficially owns 969,542 shares of Common Stock, which is equal to approximately 29.49% of the outstanding shares,
based on information from the Issuer that 3,287,647 Class A shares of Common Stock are outstanding as of March 3, 2023.
(b)
Dr. Nalluri has sole voting and dispositive power for all such shares of Common Stock held record by him.
Item 6. |
Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer
|
Not applicable
Item 7. |
Material to be Filed as Exhibits |
Not applicable
Item 8. |
Submission of Shareholders Proposals for 2023 Proxy Statement |
Not applicable
4
Date: December 8, 2023
|
|
|
Signature |
|
/s/ Anil Choudary Nalluri, M.D. |
Name/Title: |
|
Anil Choudary Nalluri, M.D. |
The original statement shall be signed by each person on whose behalf the statement is filed or his
authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of the filing person), evidence of the representatives authority to sign on behalf
of such person shall be filed with the statement: provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the
statement shall be typed or printed beneath his signature.
Attention: Intentional misstatements or omissions of fact constitute Federal
criminal violations (See 18 U.S.C. 1001)
5
Avalon Holdngs (AMEX:AWX)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Avalon Holdngs (AMEX:AWX)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024